News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 14, 2023
2023
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Read more
Oct 31, 2023
2023
Press Release Regulatory

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Read more
Sep 8, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Non-regulatory Press Release
Read more
Aug 29, 2023
2023
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Read more
Aug 10, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Non-regulatory Press Release
Read more
Jul 11, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Non-regulatory Press Release
Read more
May 16, 2023
2023
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Read more
Apr 28, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Non-regulatory Press Release
Read more
Apr 17, 2023
2023
Press Release Regulatory

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Read more
Mar 6, 2023
2023
Press Release Non-regulatory

Erik Penser Bank initiates coverage on Elicera Therapeutics

Non-regulatory Press Release
Read more
Mar 1, 2023
2023
Press Release Regulatory

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Read more
Feb 17, 2023
2023
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Read more
Feb 7, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Non-regulatory Press Release
Read more
Jan 26, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Non-regulatory Press Release
Read more
Jan 23, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Non-regulatory Press Release
Read more
Dec 7, 2022
2022
Press Release Regulatory

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Read more
Nov 18, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Read more
Nov 16, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Non-regulatory Press Release
Read more
Nov 3, 2022
2022
Press Release Regulatory

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Read more
Oct 18, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Non-regulatory Press Release
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.